86 related articles for article (PubMed ID: 28245370)
1. [Establishment and Identification of SCL-tTA/BCR-ABL Transgenic Mouse Model with Chronic Myeloid Leukemia].
Lin Y; Fu W; Liang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):24-29. PubMed ID: 28245370
[TBL] [Abstract][Full Text] [Related]
2. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
[TBL] [Abstract][Full Text] [Related]
3. Models of chronic myeloid leukemia.
Van Etten RA
Curr Oncol Rep; 2001 May; 3(3):228-37. PubMed ID: 11296133
[TBL] [Abstract][Full Text] [Related]
4. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
5. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
6. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
7. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
[TBL] [Abstract][Full Text] [Related]
8. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
Peng C; Li S
Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
[TBL] [Abstract][Full Text] [Related]
9. [Establishment of Mouse Model with Humanized Chronic Myeloid Leukemia].
Xu YJ; Jia WH; Liu CC; Chen WR; Li DP; Huang YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1329-1333. PubMed ID: 27784351
[TBL] [Abstract][Full Text] [Related]
10. Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML.
Schemionek M; Spieker T; Kerstiens L; Elling C; Essers M; Trumpp A; Berdel WE; Müller-Tidow C; Koschmieder S
Leukemia; 2012 May; 26(5):1030-7. PubMed ID: 22193968
[TBL] [Abstract][Full Text] [Related]
11. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
12. Ph-positive leukemia: a transgenic mouse model.
Groffen J; Voncken JW; Kaartinen V; Morris C; Heisterkamp N
Leuk Lymphoma; 1993; 11 Suppl 1():19-24. PubMed ID: 8251894
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.
Schemionek M; Elling C; Steidl U; Bäumer N; Hamilton A; Spieker T; Göthert JR; Stehling M; Wagers A; Huettner CS; Tenen DG; Tickenbrock L; Berdel WE; Serve H; Holyoake TL; Müller-Tidow C; Koschmieder S
Blood; 2010 Apr; 115(16):3185-95. PubMed ID: 20053753
[TBL] [Abstract][Full Text] [Related]
14. New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
Lin H; Woolfson A; Jiang X
Methods Mol Biol; 2016; 1465():187-205. PubMed ID: 27581149
[TBL] [Abstract][Full Text] [Related]
15. The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients.
Schubert C; Chatain N; Braunschweig T; Schemionek M; Feldberg K; Hoffmann M; Dufva O; Mustjoki S; Brümmendorf TH; Koschmieder S
Oncotarget; 2017 May; 8(21):34736-34749. PubMed ID: 28423730
[TBL] [Abstract][Full Text] [Related]
16. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.
Mumprecht S; Claus C; Schürch C; Pavelic V; Matter MS; Ochsenbein AF
Blood; 2009 May; 113(19):4681-9. PubMed ID: 19252140
[TBL] [Abstract][Full Text] [Related]
17. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Schulze E; Krahl R; Thalmeier K; Helbig W
Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
[TBL] [Abstract][Full Text] [Related]
18. Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.
Horváth A; Baghiu MD; Pap Z; Bănescu C; Mărginean CO; Pávai Z
Rom J Morphol Embryol; 2011; 52(3):907-13. PubMed ID: 21892537
[TBL] [Abstract][Full Text] [Related]
19. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome.
Huettner CS; Koschmieder S; Iwasaki H; Iwasaki-Arai J; Radomska HS; Akashi K; Tenen DG
Blood; 2003 Nov; 102(9):3363-70. PubMed ID: 12855552
[TBL] [Abstract][Full Text] [Related]
20. CML Mouse Model Generated from Leukemia Stem Cells.
Hu Y
Methods Mol Biol; 2016; 1465():27-35. PubMed ID: 27581136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
